摘要
目的观察达格列净联合肾康注射液治疗糖尿病肾病Ⅳ期的临床疗效。方法选择2020年1月—2022年3月临沂市中心医院收治的糖尿病肾病Ⅳ期患者92例,采用随机数字表法分为观察组和对照组,每组46例。2组患者均给予降压、控制血糖、调脂等常规治疗,对照组在常规治疗的基础上给予肾康注射液治疗,观察组在对照组治疗的基础上加用达格列净治疗,2组疗程均为4周。比较2组临床疗效、治疗前后空腹血糖(FBG)、糖化血红蛋白(HbA_(1c))、胱抑素C(CysC)、24 h尿蛋白定量(24 hUTP)、尿白蛋白/尿肌酐(UACR)、肾小球滤过率(GFR)水平。结果观察组总有效率为91.30%,高于对照组的71.74%(χ^(2)=5.845,P=0.016)。治疗4周后,2组FBG、HbA_(1c)、CysC、24 hUTP、UACR水平均低于治疗前,GFR高于治疗前,且观察组变化幅度大于对照组(P<0.01)。结论达格列净联合肾康注射液治疗糖尿病肾病Ⅳ期疗效较好,能够改善血糖水平,降低尿蛋白,改善肾功能,值得临床推广应用。
Objective To observe the clinical efficacy of dapagliflozin combined with Shenkang injection in the treatment of stageⅣdiabetes nephropathy.Methods Ninety-two patients with stageⅣdiabetes nephropathy treated in Linyi Central Hospital from January 2020 to March 2022 were selected,and they were randomly divided into observation group and control group,with 46 cases in each group.The two groups of patients were given routine treatment such as blood pressure reduction,blood sugar control and blood lipid regulation,the control group was given Shenkang injection treatment on the basis of routine treatment,and the observation group was given dapagliflozin treatment on the basis of the control group,both groups were treated for 4 weeks.The clinical efficacy,fasting blood glucose(FBG),glycosylated hemoglobin(HbA_(1c)),cystatin C(CysC),24-hour urinary protein quantification(24 hUTP),urinary albumin/creatinine(UACR)and glomerular filtration rate(GFR)levels before and after treatment were compared between the two groups.Results The total effective rate in the observation group was 91.30%,higher than 71.74%in the control group(χ^(2)=5.845,P=0.016).After 4 weeks of treatment,the levels of FBG,HbA_(1c),CysC,24 hUTP and UACR in both groups were lower than those before treatment,and the GFR was higher than that before treatment,the range of change in the observation group were greater than those in the control group(P<0.01).Conclusion Dapagliflozin combined with Shenkang injection has a significant effect in the treatment of stageⅣdiabetes nephropathy,which can improve blood sugar level,reduce urinary protein and improve renal function,and it is worthy of clinical application.
作者
徐笑群
曹爽
刘玉才
XU Xiaoqun;CAO Shuang;LIU Yucai(Linyi Central Hospital,Shandong Province,Linyi 276400,China)
出处
《临床合理用药杂志》
2023年第16期35-38,共4页
Chinese Journal of Clinical Rational Drug Use
关键词
糖尿病肾病
Ⅳ期
达格列净
肾康注射液
治疗效果
Diabetes nephropathy,stageⅣ
Dapagliflozin
Shenkang injection
Therapeutic effect
